CH625 is a potent and selective competitive inhibitor of CYP4X1 that decreases tumor burden, increases survival in glioma intracranial and subcutaneous model in rats. CH625 normalizes tumor vasculature in the C6 and GL261 gliomas through tumor-associated macrophages (TAMs) reprograming and inhibition of VEGF and TGF-β production.
potent and selective competitive inhibitor of CYP4X1 that decreases tumor burden, increases survival in gliomas
The Journal of pharmacology and experimental therapeutics, 365(1), 72-83 (2018-02-14)
Tumor-associated macrophages (TAMs) are pivotal effector cells in angiogenesis. Here, we tested whether CYP4X1 inhibition in TAMs by flavonoid CH625 prolongs survival and normalizes glioma vasculature. CH625 was selected against the CYP4X1 3D model by virtual screening and showed inhibitory
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.